Presence of onconeural antibodies in sarcoidosis patients with parasarcoidosis syndrome
- PMID: 32476961
- PMCID: PMC7247090
- DOI: 10.36141/svdld.v36i4.8745
Presence of onconeural antibodies in sarcoidosis patients with parasarcoidosis syndrome
Abstract
Background: Bothersome symptoms from sarcoidosis can develop in the absence of identified granulomas. These parasarcoidosis complaints can include small fiber neuropathy, diaphoresis, dysautonomia, and fatigue. Similar issues are also encountered in some cancer patients, especially those with onconeural antibodies.
Methods: Serum was obtained for onconeural antibody testing from sarcoidosis patients with parasarcoidosis symptoms seen at the University of Cincinnati Sarcoidosis clinic during a six month period. Detection of antibodies was performed using an onconeural antibody panel.
Results: A total of 268 patients with sarcoidosis and one or more features suggesting parasarcoidosis symptoms were enrolled in the study. Of these, 60 (22.4%) had one or more positive onconeural antibodies. In a control group of 46 non sarcoidosis patients seen in the interstitial lung disease clinic, there were only three patients with a positive antibody (Chi square=6.143, p=0.0132). A subgroup of sarcoidosis and control patients completed the small fiber neuropathy screening list. Sarcoidosis patients had a significantly higher score than the control patients (sarcoidosis: 7 [0-49] (Median [range] versus non sarcoidosis: 3 [0-31], p=0.0074). However, no significant differences were measured in the SFNL scores for sarcoidosis patients with an onconeural antibody (9 [3-36]) versus without (7 [0-49]).
Conclusion: In patients with parasarcoidosis symptoms, approximately 30% have evidence of onconeural antibody production. This may be a potential cause for parasarcoidosis symptoms in some patients.
Keywords: fatigue; onconeural; paraneoplastic; parasarcoidosis; small fiber neuropathy.
Copyright: © 2019.
Figures



Similar articles
-
Onconeural antibodies: improved detection and clinical correlations.J Neuroimmunol. 2011 Mar;232(1-2):166-70. doi: 10.1016/j.jneuroim.2010.10.009. Epub 2010 Nov 19. J Neuroimmunol. 2011. PMID: 21093932
-
Avidity of onconeural antibodies is of clinical relevance.Cancer Immunol Immunother. 2013 Aug;62(8):1393-6. doi: 10.1007/s00262-013-1442-6. Epub 2013 Jun 4. Cancer Immunol Immunother. 2013. PMID: 23733227 Free PMC article.
-
The Positive Predictive Value of Onconeural Antibody Testing: A Retrospective Review.Can J Neurol Sci. 2018 Sep;45(5):577-579. doi: 10.1017/cjn.2018.74. Can J Neurol Sci. 2018. PMID: 30234468 Review.
-
Paraneoplastic neurological syndromes in lung cancer patients with or without onconeural antibodies.J Neurol Sci. 2015 Jan 15;348(1-2):41-5. doi: 10.1016/j.jns.2014.10.040. Epub 2014 Nov 5. J Neurol Sci. 2015. PMID: 25467140
-
Which antibody and which cancer in which paraneoplastic syndromes?Pract Neurol. 2010 Oct;10(5):260-70. doi: 10.1136/jnnp.2010.224105. Pract Neurol. 2010. PMID: 20858627 Review.
Cited by
-
D. Geraint James Lecture: The sarcoidosis saga: what insights from the past will guide us in the future.Sarcoidosis Vasc Diffuse Lung Dis. 2023 Dec 20;40(4):e2023057. doi: 10.36141/svdld.v40i4.15282. Sarcoidosis Vasc Diffuse Lung Dis. 2023. PMID: 38126494 Free PMC article.
References
-
- Judson MA. The three tiers of screening for sarcoidosis organ involvement. Respir Med. 2016;113:42–9. doi: 10.1016/j.rmed.2016.02.011. Epub;%2016 Feb 23.:42-49. - PubMed
-
- JHoitsma E, De VJ, Drent M. The small fiber neuropathy screening list: Construction and cross-validation in sarcoidosis. Respir Med. 2011;105(1):95–100. - PubMed
-
- Tavee J, Zhou L. Small fiber neuropathy: A burning problem. Cleve Clin J Med. 2009;76(5):297–305. - PubMed
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical